Smith & Nephew hikes divi after beating forecasts in Q4

Medical technology group Smith & Nephew has raised its dividend by a half after a strong finish to 2012, which saw the company beat forecasts for both revenue and profit in the fourth quarter.

Medical technology group Smith & Nephew has raised its dividend by a half after a strong finish to 2012, which saw the company beat forecasts for both revenue and profit in the fourth quarter.

The board recommended a 50% increase in the final dividend to 16.2 cents per share, "reflecting our confidence in continued strategic progress and our financial strength". This pushed the total dividend for 2012 to 26.1 cents per share, also up 50%.

Revenues totalled $1,077m in the final three months of last year, down from $1,106m on a reported basis the year before due to currency exchange rates and disposals, but ahead of the consensus estimate of $1,066m. On an underlying basis, revenues increased by 3.0% year-on-year.

Underlying trading profit during the quarter increased by 2.0% to $272m, down slightly on a reported basis but still above forecasts for $260m. The company was also able to raise its trading profit margin by 10 basis points (bp) year-on-year to 25.3%.

Commenting on the results, Chief Executive Officer Olivier Bohuon said: "Smith & Nephew finished the year strongly, with both underlying Q4 revenue and trading profit up on the prior year and the completion of the Healthpoint Biotherapeutics acquisition.

"Advanced Wound Management grew at well above the market rate and the Group delivered double digit growth in the emerging markets. It was also pleasing that our Trauma performance improved."

On an underlying basis for the full year, revenues increased 2.0% to $4,137m, while trading profit rose 6% to $965m. Margins were up 80bp at 23.3%, which the company said reflected the early benefits of its 'Strategic Priorities' plan, "in particular restructuring the group to give us the right commercial models and cost structure."

Net debt rose to $288m by the end of the period (end-2011: $138m), partly due to the $782m acquisition of Healthpoint.

OutlookThe firm said that there was little change in the business environment in the Established Markets during the period, with Europe in particular continuing to be challenging. However, Emerging and International Markets delivered 14% growth and China saw revenues increase by an impressive 30%.

These market conditions are expected to be similar in 2013, according to the group's outlook statement.

However, margins are expected to fall year-on-year due to the effect of the Healthpoint acquisition and the US Medical Device excise tax.

The company said: "Smith & Nephew exited 2012 with a much stronger platform than we entered the year. In 2013 we will continue to focus on our Strategic Priorities to deliver greater value for our Company and stakeholders."

Recommended

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework
Investment strategy

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework

John Stepek talks to Steve Clapham, investor, analyst and author of The Smart Money Method, about the dangers in picking individual stocks and why you…
8 Apr 2021
BP looks set to return more money to shareholders as it beats expectations
Energy stocks

BP looks set to return more money to shareholders as it beats expectations

Oil major BP is to embark on a share buyback programme after significantly reducing its debts. Saloni Sardana looks at what it means for your portfoli…
6 Apr 2021
Deliveroo has hit the market – but it’s not getting the warmest welcome
UK stockmarkets

Deliveroo has hit the market – but it’s not getting the warmest welcome

Food delivery company Deliveroo made its debut on the stockmarket this morning. But with the share price sliding by 30% straight away, it’s not made t…
31 Mar 2021
Three stocks to buy now that will come back stronger after Covid-19
Share tips

Three stocks to buy now that will come back stronger after Covid-19

Professional investor Ed Wielechowski of Odyssean Capital, chooses three compelling stocks that should thrive in a post-pandemic world.
29 Mar 2021

Most Popular

Central banks are rushing to build digital currencies. What are they, and what do they mean for you?
Bitcoin

Central banks are rushing to build digital currencies. What are they, and what do they mean for you?

As bitcoin continues to soar in value, many of the world’s central banks are looking to emulate it by issuing their own digital currencies. But centra…
8 Apr 2021
House prices: from boom to even bigger boom
House prices

House prices: from boom to even bigger boom

UK house prices have risen to new to record highs, says Nicole Garcia Merida. Demand continues to outpace supply, but continued low interest rates, th…
9 Apr 2021
Nuclear power might never be popular – but now looks a good time to invest
Commodities

Nuclear power might never be popular – but now looks a good time to invest

Nuclear power gets a very bad press, but it is the ultimate renewable energy source. Interest in it is perking up again, says John Stepek. Which means…
9 Apr 2021